List of Excipients in Branded Drug ARGATROBAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	ARGATROBAN	argatroban	0078-0930	ALCOHOL
Novartis Pharmaceuticals Corporation	ARGATROBAN	argatroban	0078-0930	SORBITOL
Hikma Pharmaceuticals USA Inc	ARGATROBAN	argatroban	0143-9288	ALCOHOL
Hikma Pharmaceuticals USA Inc	ARGATROBAN	argatroban	0143-9288	PROPYLENE GLYCOL
Hikma Pharmaceuticals USA Inc	ARGATROBAN	argatroban	0143-9377	ALCOHOL

Generic Drugs Containing ARGATROBAN

Company	Ingredient	NDC	Excipient
Hospira Inc	argatroban	0409-1140	ALCOHOL
Hospira Inc	argatroban	0409-1140	SORBITOL
Sagent Pharmaceuticals	argatroban	25021-414	ALCOHOL
Sagent Pharmaceuticals	argatroban	25021-414	PROPYLENE GLYCOL
Sagent Pharmaceuticals	argatroban	25021-414	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in ARGATROBAN?

# Of NDCs	Excipient
10	ALCOHOL
6	PROPYLENE GLYCOL
7	SODIUM CHLORIDE
5	SORBITOL
2	WATER

# Argatroban Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Argatroban is an established injectable direct thrombin inhibitor with limited active-ingredient patent protection and a formulation profile that creates practical opportunities. The commercial opportunity is concentrated in ready-to-use hospital products, ethanol-reduced or ethanol-free formulations, pediatric and critical-care presentations, improved container compatibility, and international supply reliability. The principal regulatory route for a conventional generic is an ANDA under section 505(j), while materially different concentrations, delivery systems, or clinical-use claims may require a 505(b)(2) application.

What is the current FDA status of argatroban?

Argatroban is FDA-approved for anticoagulation in adults with heparin-induced thrombocytopenia and for patients with or at risk of HIT undergoing percutaneous coronary intervention. It is administered intravenously and requires dose adjustment in hepatic impairment. Renal dysfunction generally has less impact on clearance than hepatic dysfunction, which supports use in selected dialysis and critical-care settings.[1]

Item	Argatroban status
Active ingredient	Argatroban
Pharmacology	Direct thrombin inhibitor
Primary indication	Treatment of HIT
Additional indication	PCI in patients with HIT or risk of HIT
Dosage form	Sterile intravenous injection or infusion
FDA approval	Original NDA approved in 2000
Regulatory category	Small-molecule drug
Biosimilar pathway	Not applicable
Generic pathway	ANDA, subject to pharmaceutical equivalence
Principal users	Hospitals, intensive-care units, cardiology, hematology, dialysis services

The marketed product is a parenteral drug administered in a controlled clinical environment. That limits retail substitution but makes manufacturing consistency, premix convenience, vial configuration, labeling, and hospital purchasing important commercial factors.

What excipients are used in argatroban injection?

Commercial argatroban injection products commonly use ethanol and sorbitol in an aqueous injectable formulation. The FDA labeling for argatroban injection identifies argatroban, sorbitol, ethanol, water for injection, and pH-adjusting agents as formulation components.[1,2]

Excipient or component	Functional role	Commercial consideration
Ethanol	Solvent and solubility aid	Creates exposure, handling, labeling, and patient-population concerns
Sorbitol	Tonicity and formulation aid	May create compatibility or patient-specific tolerability considerations
Water for injection	Vehicle	Standard sterile parenteral vehicle
Sodium hydroxide or hydrochloric acid	pH adjustment	Controls stability and injectability
Container and closure system	Product integrity	Critical for adsorption, extractables, leachables, and shelf life

The presence of ethanol is the clearest formulation differentiation point. It can complicate use in neonates, pediatric patients, patients with alcohol sensitivity, patients with severe hepatic dysfunction, and institutions seeking to reduce excipient exposure. The actual exposure depends on concentration, infusion rate, treatment duration, patient weight, and the final dilution used by the hospital.

Argatroban products should not be evaluated only by nominal active-ingredient concentration. The commercial formulation includes a solvent system, pH profile, container, infusion dilution, in-use stability, and compatibility with administration sets. These factors can create meaningful differences even when the active ingredient is identical.

What excipient strategies are available for argatroban?

The highest-value strategy is to improve administration without compromising solubility, stability, potency, or infusion compatibility.

Ethanol-reduced or ethanol-free formulations

An ethanol-free product would address the most visible weakness in the legacy formulation. Potential approaches include:

• A redesigned aqueous solvent system.
• A higher-solubility argatroban salt or pH-controlled formulation.
• A concentrated product that uses a lower total excipient burden after dilution.
• A lyophilized or reconstituted presentation, if stability and reconstitution time are commercially acceptable.
• A ready-to-use solution with a different buffer and tonicity system.

The main development risks are precipitation, potency loss, pH drift, container adsorption, sterilization stress, and limited shelf life. Replacing ethanol with propylene glycol, polyethylene glycol, or other co-solvents would not automatically create a superior product. Each alternative introduces its own toxicology, extractables, labeling, and pediatric-use questions.

Ready-to-use premixed bags

Premixed argatroban can reduce pharmacy compounding, calculation errors, and preparation time. A 250 mg/250 mL presentation at 1 mg/mL is commercially intuitive for hospital infusion workflows. Smaller bags or syringes may be useful for pediatric, procedural, or short-duration applications.

The product opportunity is strongest where the formulation can provide:

• Longer shelf life.
• Reduced preparation steps.
• Clear infusion-rate labeling.
• Standardized concentration.
• Compatibility with common pumps and tubing.
• Reduced waste after dose changes.
• Reliable supply during anticoagulant shortages.

A premixed bag may qualify as a conventional generic if it matches the reference product’s relevant quality and performance characteristics. A materially different concentration, container, or administration system may require a 505(b)(2) analysis.

Low-volume concentrate

A concentrated vial can reduce storage volume and shipping cost. It also allows hospitals to prepare the final concentration according to patient weight and infusion protocol. The tradeoff is greater compounding responsibility and a higher risk of dilution errors.

The strongest commercial configuration may be a dual portfolio:

1. A concentrated vial for high-volume tertiary hospitals and customized dosing.
2. A premixed bag or syringe for emergency, intensive-care, and smaller hospitals.

Pediatric and neonatal formulation

Pediatric use creates a potential differentiation segment because dose requirements are weight-based and infusion volumes can be small. A low-volume, low-excipient product could have value in neonatal and pediatric intensive-care units.

A pediatric formulation would face higher scrutiny for ethanol, sorbitol, preservative exposure, dosing accuracy, and device dead volume. If supported by clinical data and labeling, a pediatric presentation could justify a 505(b)(2) strategy or a supplemental regulatory approach rather than a standard ANDA.

Container and administration-system improvements

Argatroban is a low-dose continuous infusion drug. Container selection can affect drug recovery and dose accuracy. Development work should evaluate:

• Polyolefin bags.
• Glass vials.
• Syringe systems.
• Tubing adsorption.
• Low-binding administration sets.
• Light exposure.
• Freeze-thaw and shipping conditions.
• In-use stability after dilution.
• Compatibility with common diluents.

A container-closure or device patent may be more defensible than a broad composition claim if the active ingredient and basic formulation are already well established.

What patents protect argatroban?

The original argatroban active-ingredient patent estate is expired. U.S. Patent No. 4,258,192, assigned to Mitsubishi Chemical Industries, covered argatroban-related compounds and was filed in 1979 and issued in 1981. Its ordinary patent term expired decades ago.[3]

Patent	Subject matter	Status
U.S. Patent No. 4,258,192	Argatroban-related compounds and anticoagulant use	Expired
Later product and formulation rights	Product-specific formulation, manufacturing, or use claims	Must be assessed by jurisdiction and claim scope
Current active-ingredient exclusivity	Argatroban molecule	None expected

Argatroban therefore has a relatively low active-ingredient patent barrier. The commercial risk is more likely to arise from regulatory requirements, manufacturing controls, supply reliability, hospital contracting, and formulation-specific intellectual property than from an unexpired composition-of-matter patent.

What is the Orange Book status of argatroban?

Argatroban is an old small-molecule injectable drug. The Orange Book framework remains relevant for the reference NDA, therapeutic-equivalence evaluations, and any listed patents, but it is not a biosimilar product and does not depend on biologic interchangeability.

The current commercial analysis should distinguish among:

• The original NDA.
• Approved ANDAs.
• Product-specific patents listed in the Orange Book.
• Unlisted formulation, manufacturing, trade-secret, or device rights.
• Regulatory exclusivity that has already expired.

There is no apparent remaining NCE exclusivity for argatroban. The original five-year NCE exclusivity period would have ended in 2005, assuming the original FDA approval date in 2000.[1,4]

An applicant should not assume that absence of an Orange Book patent creates unrestricted freedom to operate. Unlisted patents can cover manufacturing processes, container systems, premix configurations, dosing devices, or specialized formulations. Those rights may still be relevant even if they do not block an ANDA under the Orange Book patent-certification process.

When does argatroban lose exclusivity?

Argatroban lost its principal exclusivity barriers years ago.

Exclusivity category	Approximate endpoint
Original U.S. composition patent	2000
Five-year NCE exclusivity	2005
Current NCE exclusivity	Expired
Pediatric exclusivity	No material current barrier expected
Orphan-drug exclusivity	Not the principal commercial protection
Biosimilar exclusivity	Not applicable

The relevant launch question is not whether the molecule remains exclusive. It is whether a new entrant can obtain approval with an economically viable formulation, supply chain, and hospital-sales strategy.

Which companies compete in argatroban?

Competition includes the original branded product lineage and multiple generic manufacturers. U.S. hospital supply has included products from companies such as Hikma, Fresenius Kabi, Sagent Pharmaceuticals, and other generic or injectable suppliers, depending on market period and product availability.[2,5]

The market is fragmented by:

• Vial concentration.
• Premixed bag availability.
• Hospital group purchasing organization contracts.
• Back-order history.
• Manufacturing site reliability.
• Shelf life.
• Product presentations.
• Contract-pharmacy and wholesaler relationships.

The strongest competitor is often the supplier that can maintain uninterrupted availability rather than the supplier with the lowest nominal price. Injectable shortages can shift hospital contracts rapidly, but those gains may reverse when supply normalizes.

What commercial opportunities exist for argatroban excipients?

Hospital premix and workflow reduction

A ready-to-use product can command a commercial premium if it reduces pharmacy labor and preparation risk. The value proposition is strongest in hospitals with high anticoagulation volume, limited pharmacy staffing, or strict compounding controls.

Ethanol-free positioning

An ethanol-free product could target pediatric hospitals, critical-care units, and institutions with excipient-reduction policies. The claim must be supported by labeling and formulation data. Marketing should focus on measurable product attributes rather than broad safety claims.

Critical-care and ECMO use

Argatroban is used in specialized anticoagulation settings, including selected extracorporeal membrane oxygenation and renal-replacement protocols. These uses can generate demand for standardized concentrations, infusion compatibility, and rapid access, even when they are not the principal FDA-labeled indication.[6]

Dialysis and renal-replacement protocols

Argatroban’s hepatic clearance profile can make it useful when heparin is unsuitable and renal function is impaired. Formulations designed for predictable dilution and continuous infusion may be attractive to dialysis providers and tertiary hospitals.

International licensing

Because the active ingredient is old and generic, the more realistic licensing assets are:

• A differentiated formulation.
• A validated premix manufacturing process.
• A regional sterile-injectable facility.
• A device or low-adsorption administration system.
• Regulatory dossiers in markets where supply is limited.
• Hospital contracts and distribution rights.

A license based only on the argatroban molecule is unlikely to command substantial value. A license combining formulation rights, regulatory approvals, manufacturing capacity, and supply commitments has greater commercial relevance.

How strong is the patent estate for argatroban?

The active-ingredient patent estate is weak because the foundational patent has expired. A new formulation estate could be moderately defensible if it contains a narrow technical solution supported by comparative data.

IP category	Relative strength	Key requirements
New argatroban composition claim	Low	Novel chemical entity or salt with unexpected advantages
Ethanol-free formulation	Moderate	Demonstrated stability, solubility, and clinical or handling benefit
Premixed bag	Low to moderate	Specific composition, concentration, container, or stability profile
Pediatric dosage form	Moderate	Distinct formulation and supporting clinical or usability data
Manufacturing process	Moderate	Reproducible process with measurable quality or yield advantage
Container or tubing system	Moderate	Demonstrated reduction in adsorption or dose loss
Method-of-use claim	Variable	New, non-obvious patient population or dosing regimen
Trade secret	Moderate	Process knowledge that is difficult to reverse engineer

The best patent strategy would combine composition, concentration, container, stability, and use claims. Broad claims covering “argatroban with a solvent” are vulnerable to invalidity challenges because the drug and injectable formulation are old. Narrow claims tied to a defined excipient range and unexpected stability or compatibility result are more credible.

What generic entry risks exist for argatroban?

Generic entry risk is high because:

• The molecule is long off patent.
• NCE exclusivity has expired.
• The product is a conventional small-molecule injectable.
• No biosimilar development is required.
• Clinical development requirements are generally lower than for a new chemical entity.
• Hospital purchasers can substitute among therapeutically equivalent products.

Entry barriers remain meaningful in practice. Sterile manufacturing, process validation, extractables and leachables, stability studies, container compatibility, and shortage-risk management can delay approval or limit commercial scale.

A generic applicant may use a Paragraph IV certification if an applicable listed patent remains in the Orange Book. Given the age of argatroban, the more likely certification issues concern any later-listed formulation or method patents rather than the original molecule. A Paragraph IV challenge would be commercially relevant only if a listed patent remains enforceable and has sufficient remaining term to delay approval.

What patent litigation or settlements affect argatroban?

No major, widely reported current patent litigation or settlement appears to define the U.S. argatroban market. The absence of a prominent dispute is consistent with an old molecule whose foundational patent has expired and whose market is supplied primarily through generic injectable products.

Potential disputes would more likely involve:

• A later formulation patent.
• A premix concentration.
• A container or administration system.
• Manufacturing-process infringement.
• ANDA-related patent certification.
• Contractual or supply obligations rather than molecule ownership.

How does argatroban compare with competing anticoagulants?

Product	Class	Main advantage	Main commercial limitation
Argatroban	Direct thrombin inhibitor	Useful in HIT and hepatic-clearance setting	Continuous IV infusion and monitoring
Bivalirudin	Direct thrombin inhibitor	Broad procedural use and short activity	Cost, renal considerations, procedural positioning
Fondaparinux	Indirect factor Xa inhibitor	Subcutaneous administration	Less flexible for rapidly changing critical-care dosing
Danaparoid	Indirect anticoagulant	Used in some HIT markets	Limited availability and geographic coverage
Unfractionated heparin	Indirect thrombin inhibitor	Low cost and reversibility	Not suitable for patients with HIT
Direct oral anticoagulants	Oral factor Xa or thrombin inhibitors	Outpatient convenience	Not substitutes for unstable, rapidly titrated IV anticoagulation

Argatroban’s excipient opportunity exists because its key use cases require inpatient infusion. Convenience and formulation tolerability can matter more than consumer branding.

What is the revenue exposure and market outlook?

Product-level revenue for argatroban is generally not disclosed separately by diversified manufacturers. The addressable market is narrower than that of oral anticoagulants because argatroban is primarily a hospital-administered infusion used in a defined clinical population.

Revenue opportunity is concentrated in:

• Institutional contracts.
• Shortage replacement.
• Premixed infusion products.
• Specialty hospital accounts.
• Pediatric and critical-care formulations.
• International markets with limited generic supply.
• Contract manufacturing and private-label supply.

A conventional vial-only generic is likely to compete mainly on price and availability. A differentiated premix or excipient-reduced product can compete on total treatment cost, pharmacy labor, error reduction, and supply continuity.

Key Takeaways

• Argatroban’s foundational composition patent and original exclusivity periods have expired.
• The drug is a small-molecule injectable, so biosimilar risk does not apply.
• Current value is concentrated in formulation, manufacturing, supply, and hospital-distribution assets.
• Ethanol reduction or elimination is the clearest excipient differentiation opportunity.
• Premixed bags, low-volume syringes, pediatric presentations, and low-adsorption administration systems are commercially relevant.
• A conventional generic would generally pursue an ANDA; materially different formulations may require a 505(b)(2) pathway.
• Orange Book analysis should be separated from unlisted formulation, process, container, and trade-secret rights.
• Patent strength for a new argatroban product will depend on narrow technical claims supported by comparative stability, compatibility, or clinical-use data.
• Generic entry risk is high, but sterile manufacturing and supply reliability remain practical barriers.
• The strongest commercial asset is likely a reliable, ready-to-use hospital product rather than a new active-ingredient patent.

FAQs

Can argatroban be reformulated without ethanol?

Yes. An ethanol-free formulation is technically possible, but it must maintain solubility, chemical stability, sterility, dilution performance, and container compatibility. A substantially different formulation may require regulatory support beyond a conventional ANDA.

Is argatroban a good candidate for a 505(b)(2) application?

It can be, particularly for an ethanol-free formulation, new concentration, pediatric presentation, or novel delivery system. The pathway depends on the extent of formulation and labeling differences from the approved reference product.

Are argatroban excipients eligible for patent protection?

Yes, if the formulation contains a novel and non-obvious combination or range that produces a demonstrated technical benefit. Claims directed only to routine substitution of known injectable excipients would face greater validity risk.

What is the best commercial presentation for argatroban?

A ready-to-use premixed bag is likely the strongest workflow-oriented presentation, while a concentrated vial remains useful for hospitals that customize infusion volumes. A portfolio containing both formats can address different hospital protocols.

Does argatroban have biosimilar competition?

No. Argatroban is a chemically synthesized small molecule. Competition occurs through generic-drug approval, not the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2000). Argatroban injection prescribing information. FDA.
2. DailyMed. (n.d.). Argatroban injection, solution. National Library of Medicine.
3. U.S. Patent and Trademark Office. (1981). U.S. Patent No. 4,258,192: Argatroban and salts thereof.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
6. Extracorporeal Life Support Organization. (2021). ELSO guidelines for anticoagulation monitoring and management. ELSO.